Free Trial

Neo Ivy Capital Management Purchases Shares of 29,162 Albemarle Corporation (NYSE:ALB)

Albemarle logo with Basic Materials background

Key Points

  • Neo Ivy Capital Management has acquired 29,162 shares of Albemarle Corporation (NYSE:ALB), valued at approximately $2.1 million, marking a new position for the firm in the specialty chemicals sector.
  • A recent report indicates that institutional investors own 92.87% of Albemarle's stock, highlighting strong interest from major financial players.
  • Albemarle recently announced a quarterly dividend of $0.405 per share, with an annualized yield of 1.93%, set to be paid on October 1st to shareholders of record.
  • Interested in Albemarle? Here are five stocks we like better.
  • Limited Time Offer: Unlock powerful research tools, advanced financial data, and expert insights to help you invest with confidence. Save 50% when you upgrade to MarketBeat All Access during the month of July. Claim your discount here.

Neo Ivy Capital Management acquired a new position in Albemarle Corporation (NYSE:ALB - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 29,162 shares of the specialty chemicals company's stock, valued at approximately $2,100,000.

Other institutional investors also recently modified their holdings of the company. Pilgrim Partners Asia Pte Ltd bought a new stake in shares of Albemarle in the fourth quarter worth $34,000. Orion Capital Management LLC bought a new stake in Albemarle during the fourth quarter valued at $35,000. SJS Investment Consulting Inc. bought a new stake in Albemarle during the first quarter valued at $32,000. Allianz SE bought a new stake in Albemarle during the fourth quarter valued at $44,000. Finally, Chapman Financial Group LLC bought a new stake in Albemarle during the fourth quarter valued at $60,000. Institutional investors own 92.87% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on ALB shares. Wall Street Zen raised shares of Albemarle to a "sell" rating in a research report on Monday, May 5th. Morgan Stanley cut their price target on shares of Albemarle from $68.00 to $58.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Mizuho set a $76.00 price objective on shares of Albemarle in a research report on Tuesday, July 15th. Wells Fargo & Company increased their price objective on shares of Albemarle from $60.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Monday, July 14th. Finally, UBS Group set a $57.00 price objective on shares of Albemarle and gave the stock a "sell" rating in a research report on Friday, July 11th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $91.00.

View Our Latest Report on ALB

Albemarle Stock Down 0.4%

Shares of ALB traded down $0.34 on Friday, reaching $83.84. The company's stock had a trading volume of 5,377,902 shares, compared to its average volume of 4,448,243. The company has a current ratio of 2.11, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. Albemarle Corporation has a twelve month low of $49.43 and a twelve month high of $113.91. The stock has a market capitalization of $9.87 billion, a PE ratio of -7.54 and a beta of 1.63. The firm has a fifty day moving average of $64.81 and a 200-day moving average of $69.89.

Albemarle (NYSE:ALB - Get Free Report) last posted its earnings results on Wednesday, April 30th. The specialty chemicals company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.62) by $0.44. Albemarle had a negative net margin of 22.39% and a negative return on equity of 1.92%. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same quarter in the prior year, the business posted $0.26 EPS. The firm's revenue was down 20.9% compared to the same quarter last year. Equities analysts predict that Albemarle Corporation will post -0.04 EPS for the current year.

Albemarle Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 1st. Shareholders of record on Friday, September 12th will be paid a $0.405 dividend. The ex-dividend date of this dividend is Friday, September 12th. This represents a $1.62 annualized dividend and a yield of 1.93%. Albemarle's dividend payout ratio (DPR) is -14.57%.

About Albemarle

(Free Report)

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.

Featured Stories

Institutional Ownership by Quarter for Albemarle (NYSE:ALB)

Should You Invest $1,000 in Albemarle Right Now?

Before you consider Albemarle, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Albemarle wasn't on the list.

While Albemarle currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines